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Introduction
Chronic obstructive pulmonary disease (COPD) remains the fourth leading cause of death worldwide, although it is both preventable and treatable. It is a major cause of morbidity and mortality, and its economic and social burden is projected to increase in the coming decades owing to increased risk factors and aging of the population. 1 Although characterized by the expiratory airflow (measured by forced expiratory volume in 1 second [FEV 1 ]), COPD is associated with an increased incidence of comorbidities such as cardiovascular (CV) disease, musculoskeletal impairment, and diabetes mellitus, which can affect outcomes and may result in unanticipated adverse events (AEs). In addition, patients are often prescribed a number of medications for the management of the concomitant diseases, as well as their COPD, and therefore it , Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany) is an inhaled, once-daily, long-acting anticholinergic bronchodilator indicated for maintenance therapy in patients with COPD, 1 and has been shown to improve lung function, health-related quality of life (HRQoL), dyspnea, and exercise tolerance. [2] [3] [4] [5] [6] Tiotropium has also been shown to reduce the number and risk of exacerbations (including exacerbations leading to hospitalization), and to delay the time to first exacerbation. 5, [7] [8] [9] Tiotropium has been available since 2002 5, [12] [13] [14] [15] and are well established in most countries, with tiotropium HandiHaler ® being the most prescribed COPD maintenance treatment worldwide (with more than 31 million patient-years of use). 16 Results from the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT ® ) trial, which permitted the concomitant use of long-acting β 2 agonists (LABAs) and theophylline, demonstrated fewer fatal AEs (FAEs) with tiotropium HandiHaler ® versus placebo and no CV safety issues. 5, 17 In contrast, a post hoc pooled analysis of 6,096 patients in three 1-year trials and one 6-month trial using patient-level data and including vital status data of early discontinued patients showed numerically more deaths with tiotropium Respimat ® 5 µg versus placebo, concentrated in patients with known cardiac rhythm disorders at study baseline. 11, 18 Subsequent meta-analyses based on aggregated data and reviews of the same Respimat ® trial data have suggested there might be a significantly increased risk of death with tiotropium Respimat ® versus placebo [19] [20] [21] [22] ; however, other meta-analyses, based on individual participant data, did not confirm this relationship between tiotropium HandiHaler ®23-28 or Respimat ®24 and CV or FAEs versus placebo in patients with COPD. Findings from the initial pooled safety analysis of tiotropium Respimat ®11,18 drove the initiation of the large TIOtropium Safety and Performance In Respimat ® (TIOSPIR™) trial (n=17,135), in which patients were treated over an average period of 2.3 years. The primary endpoint of TIOSPIR™ was noninferiority in all-cause mortality of Respimat ® versus HandiHaler ® . The TIOSPIR™ trial demonstrated similar safety (including fatal and CV events) and efficacy profiles for tiotropium Respimat ® 2.5 and 5 µg, and HandiHaler ® 18 µg, including patients with cardiac arrhythmias at baseline. 29 The purpose of this report is to describe the findings of all placebo-controlled tiotropium HandiHaler ® 
Methods study population
This pooled safety analysis followed a similar methodology to those described by Kesten et al 26 and Celli et al 24 and describes the risk of AEs by calculating a rate ratio (RR). Data from 35 Phase III and IV tiotropium clinical trials completed as of July 2012 (listed in Table 1 ) were included. Of these, 28 trials used tiotropium bromide dry powder (delivered via HandiHaler ® 18 µg once daily), and 7 trials used tiotropium bromide solution (delivered via Respimat ® 5 µg once daily). All placebocontrolled, double-blind, and parallel-group COPD trials of $4 weeks' duration were included in the analysis.
The trials used similar inclusion and exclusion criteria. Patients who had a diagnosis of COPD with FEV 1 #70% of forced vital capacity, who were aged $40 years and had $10 pack-years of smoking history were eligible for inclusion. Exclusion criteria included a diagnosis of asthma, symptomatic prostatic hypertrophy or bladder neck obstruction, narrow-angle glaucoma, and known hypersensitivity to trial medication or components. Patients with significant disease other than COPD that could significantly confound the trial results or preclude trial completion were also excluded. Other exclusion criteria in earlier trial protocols were heart failure resulting in hospitalization in the previous 3 years, cardiac arrhythmia requiring drug treatment, or myocardial infarction (MI) within the past year. Other than these specific criteria, heart failure and ischemic heart disease were not excluded. More recent trials used less stringent exclusion criteria, such as life-threatening cardiac arrhythmia or arrhythmia requiring a change in medication within the last year, heart failure resulting in hospitalization in the past year, and/or MI within the preceding 6 months. In study 205.235 (UPLIFT 
adverse event reporting
AEs occurring during the period at risk (defined as the period during which the patient received the study drug and up to 30 days thereafter) were reported by the investigator.
Definitions of AEs and serious AEs (SAEs) followed the International Conference on Harmonisation guidelines. 30 The cause of death was adjudicated by a Clinical Endpoints Committee in studies 205.235 and 205.372 only. Therefore, the investigator-reported preferred terms (PTs) were used for the pooled analysis rather than the adjudicated terms. 
Categorization of aes

242
halpin et al so-called system organ classes (SOCs). In some cases, the PTs are assigned to more than one SOC, in which case the "primary" SOC that was most relevant to the AE has been selected. To capture clinical endpoints of interest more comprehensively, and to improve the precision of rate estimates, PTs from different SOCs were combined and referred to as pharmacovigilance (PV) endpoints. Where feasible and appropriate, in order to standardize and facilitate comparability, standardized MedDRA queries (SMQs) have been used, rather than PV endpoints. A similar approach has been used and is described in previous publications. 24, 26 A composite endpoint of major adverse CV events (MACE) was included in the analysis. The composite endpoint represented FAEs in the SOC cardiac disorders and SOC vascular disorders combined with MI (fatal and nonfatal), stroke (fatal and nonfatal), and the sudden death, sudden cardiac death, and cardiac death PTs. MACE with fatal outcomes are referred to as fatal MACE. The clinical endpoint MI was defined by the sub-SMQ MI (broad), while for the clinical endpoint of "stroke," a PV endpoint was used in the analysis.
An individual patient may be represented in several PTs but was represented only once when the data were displayed according to a pooled term, ie, SOC, PV endpoint/SMQ, or MACE.
statistical analysis
In order to adjust for treatment durations in the different clinical trials, incidence rates (IRs) were computed as follows: the number of patients experiencing an event/patient-years at risk. Time at risk was the time from start of treatment to onset of a predetermined event. For patients who did not experience a specific event, the shortest of either the time to death or the time to end of treatment +30 days was used (on-treatment analysis).
To measure the strength of the effect, incidence RRs of tiotropium versus placebo were calculated on the basis of a Cochran-Mantel-Haenszel test stratified by trial. To indicate the stability or precision of the effect estimate, the width of the 95% confidence intervals (CI) was utilized. An RR.1 indicates an increased risk with tiotropium, and an RR,1 indicates a decreased risk with tiotropium. 
Results
study population
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Tiotropium: pooled safety analysis Table 4 Irs (per 100 patient-years) and rrs for cardiac, vascular, and respiratory aes Table s1 for details). e sMQ ischemic heart disease sub-sMQ other ischemic heart disease (broad).
f sMQ ischemic heart disease subsMQ MI (broad). Abbreviations: AE, adverse event; AF, atrial fibrillation; CI, confidence interval; COPD, chronic obstructive pulmonary disease; IR, incidence rate; MI, myocardial infarction; PV, pharmacovigilance; RR, rate ratio; SMQ, standardized
Medical Dictionary for regulatory activities queries; sOC, system organ class.
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halpin et al Table 5 Irs (per 100 patient-years) and rrs for cardiac, vascular, and respiratory saes Table s1 for details). e sMQ ischemic heart disease sub-sMQ other ischemic heart disease (broad).
f sMQ ischemic heart disease subsMQ myocardial infarction (broad). Abbreviations: AF, atrial fibrillation; CI, confidence interval; COPD, chronic obstructive pulmonary disease; IR, incidence rate; MI, myocardial infarction; PV, pharmacovigilance; RR, rate ratio; SAE, serious adverse event;
sMQ, standardized Medical Dictionary for regulatory activities queries; sOC, system organ class. (Table 7) . Gastrointestinal obstruction, dyspepsia, dysuria, and gastroesophageal reflux also increased with tiotropium use. The incidence of glaucoma or the worsening of an existing glaucoma at baseline was not increased with tiotropium, as shown by an RR close to 1 (RR [95% CI]: 0.97 [0.62, 1.52]). There was no increased risk for metabolism and nutrition, nervous system, and psychiatric AEs (Table 7) . Potential anticholinergic SAEs were not associated with an increased risk with tiotropium (Table 8) . Similar results were obtained for anticholinergic AEs and SAEs occurring when the HandiHaler ® and Respimat ® groups were analyzed separately (data not shown). Table s1 for details). Significantly different from 1. e sMQ gastrointestinal perforation, ulceration, hemorrhage, or obstruction.
Fatal events
f sMQ hyperglycemia/new-onset diabetes mellitus (narrow).
g sMQ depression and self-injury (excluding suicide and self-injury) (narrow). Abbreviations: AE, adverse event; CI, confidence interval; IR, incidence rate; PV, pharmacovigilance; RR, rate ratio; SMQ, standardized Medical Dictionary for Regulatory activities queries; sOC, system organ class. Table s1 for details).
d sMQ gastrointestinal perforation, ulceration, hemorrhage, or obstruction. e sMQ hyperglycemia/new-onset diabetes mellitus (narrow). f sMQ depression and self-injury (excluding suicide and self-injury) (narrow). Abbreviations: Ir, incidence rate; PV, pharmacovigilance; rr, rate ratio; sae, serious adverse event; sMQ, standardized Medical Dictionary for regulatory activities queries; sOC, system organ class.
tiotropium Respimat ® , in particular relating to safety. This led to the development of the present pooled safety analysis, and provides the justification for the pooling of both inhaler types. Additionally, the pooled studies had similar entry criteria, assessment procedures, and data collection methods; the patient baseline characteristics were also comparable between the HandiHaler ® and Respimat ® trials. This pooled safety analysis shows that IRs for overall AEs and SAEs were significantly lower in the tiotropium group compared with those in the placebo group, while the incidence of FAEs was numerically lower in the tiotropium group. In the tiotropium HandiHaler ® group, IRs were significantly lower for all AEs, while for the tiotropium Respimat 62 Cooper et al 63 Voshaar et al 35 Voshaar et al 35 Bateman et al 36 Bateman et al 36 Bateman et al 12 Littner et al 64 Abrahams mouth, constipation, intestinal obstruction, and urinary retention) were more frequent in the tiotropium versus placebo groups, although SAEs were not. The large patient database size and large tiotropium exposure in terms of patient years provide a robust estimate of the IRs for these effects and allow a sound assessment of risks and benefits with tiotropium HandiHaler ® and Respimat ® in patients with COPD.
We have carried out further analysis on patients with renal impairment. The results were presented at the European Respiratory Society Annual Congress 2014. 31 The safety of tiotropium was analyzed in trials where creatinine clearance was reported at baseline. Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; FAE, fatal adverse event; IR, incidence rate; MI, myocardial infarction; PT, preferred term; RR, rate ratio; SOC, system organ class. The findings of our analysis contrast with retrospective analyses regarding CV events and inhaled anticholinergics, which suggested that CV deaths were increased with inhaled anticholinergic, in particular with ipratropium. 33, 34 Limitations to these meta-analyses have been described previously, 24 and include improper design due to lack of data, errors in article identification and data extraction, as well as improper accounting for differential trial discontinuation. A mortality imbalance was seen with tiotropium Respimat ® in a pooled analysis of three 1-year trials and one 6-month trial, 11, 18 and with subsequent meta-analyses. [19] [20] [21] [22] These meta-analyses were based on the same trials as the present review, but were carried out differently. In the Singh et al 22 NCT00168831, 36 and NCT00387088), tiotropium Respimat ® was associated with an increased risk of FAEs. These analyses were limited due to imprecise estimates owing to fairly low event rates and were performed on published aggregated on-treatment data, including the higher 10 µg dose, rather than using individual patient data, possibly leading to bias.
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The Dong et al 19 meta-analysis, which also associated tiotropium Respimat ® with a higher risk of FAEs, in particular for CV death, in patients with severe COPD and in those at a higher daily dose (10 µg), only used three Respimat ® trials (NCT00168844, 36 NCT00168831, 36 and NCT00387088 12 ). All of the trials included in these meta-analyses were also included in the current analysis, which totaled seven Respimat ® trials (all placebo-controlled trials available to date). The high number of patients and patient-years of exposure to tiotropium included in our review, and especially the use of individual patient data, ensures the robustness of the analysis.
Although most prospective, randomized, double-blind, clinical trials with tiotropium HandiHaler ® and Respimat ® in COPD have been conducted by Boehringer Ingelheim and are included in this analysis, a few other studies have been carried out. The Investigating New Standards for Prophylaxis In Reduction of Exacerbations (INSPIRE) study observed an increase in mortality in the tiotropium (HandiHaler ® ) group compared with the salmeterol and fluticasone groups. However, the interpretation beyond the primary exacerbation endpoint should be done with caution as the withdrawal of the run-in medication, salmeterol and oral prednisolone (30 mg) , at the time of randomization may also have affected the outcome and results of this trial. 37, 38 Additional studies of tiotropium HandiHaler ® were performed in an open-label fashion, for which patient-level data were not available. 39, 40 International Journal of COPD 2015:10 submit your manuscript | www.dovepress.com
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Tiotropium: pooled safety analysis Pooling clinical data into meta-analyses includes such limitations as differences in trial populations, trial design, and physician diagnostic reporting. However, the present safety review reduced these limitations by analyzing the data on a patient level and controlling for differences in exposure between treatment groups, therefore reducing bias and confounding. In addition, the analysis of patient-level data also allows grouping of AEs, such as SMQs, PV endpoints, and subgroup analyses defined by potential risk factors. Potential problems in combining studies have been minimized because the trials were conducted using consistent inclusion and exclusion criteria, the same diagnostic criteria, and nearly identical approaches to data collection. A potential limitation may arise from the accuracy of causes of death reported by investigators, as only a few trials had an adjudication committee (studies 205.235 and 205.372). However, for consistency with data capture for AEs, SAEs, and other trials, the investigator-reported causes were used for the pooled analysis rather than the adjudicated terms from the clinical endpoints committee.
In our analysis, some HandiHaler ® trials (such as UPLIFT ® and 205.266) as well as the Respimat ® trials had relatively broad inclusion criteria (including patients with stable cardiac disorders), and allowed concomitant respiratory medication including ICS, LABAs, and theophylline. Therefore, the patient population analyzed here generally reflects real-world heterogeneous populations and phenotypes of patients with COPD, as far as is possible in randomized, controlled trials. The absolute rates of FAEs observed for the groups reported in this analysis (IR/100 patient-years: 3.71 and 3.27 for the placebo and tiotropium groups, respectively) are comparable with those of mortality in general in COPD for which observed mortality IRs are 1.7-2.2 for Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage 2 patients and 3.07-4.29 for GOLD Stage 3 and 4 patients. 41, 42 Furthermore, the increased size of the safety database, pooling 35 studies to include 12,929 tiotropium-treated patients, providing 14,909 patient-years' exposure to tiotropium, provides a robust dataset.
In summary, the present analysis describes the pooled safety data for tiotropium HandiHaler ® (28 trials) and Respimat ® (7 trials), as well as by inhaler type, in 24,555 patients and 14,909 patient-years of exposure to tiotropium. The results indicate that tiotropium, given via either HandiHaler ® or Respimat ® , does not increase the overall risks of AEs, SAEs, FAEs, or CV events. Given the evidence, provided by the TIOSPIR™ trial, that both have an equal safety profile, and given their established efficacy in terms of bronchodilation, reduction in exacerbations, and improvement in HRQoL, physicians may consider tiotropium in either formulation depending on availability and their preference or that of the patient. angle closure glaucoma; borderline glaucoma; developmental glaucoma; diabetic glaucoma; fundoscopy abnormal; glaucoma; glaucoma drug therapy; glaucoma surgery; glaucoma traumatic; glaucomatocyclitic crises; glaucomatous optic disc atrophy; gonioscopy abnormal; halo vision; intraocular pressure; fluctuation; intraocular pressure increased; intraocular pressure test abnormal; iridotomy; loss of visual contrast sensitivity; normal tension glaucoma; ocular hypertension; open angle glaucoma; ophthalmic fluid drainage; optic discs blurred; optic nerve cup/disc ratio increased; optic nerve cupping; phacolytic glaucoma; phacotrabeculectomy; pigmentary glaucoma; pupillary light reflex tests abnormal; slit-lamp tests abnormal; trabeculectomy; trabeculoplasty; visual field tests abnormal headache Basilar migraine; chronic paroxysmal hemicrania; cluster headache; complicated migraine; drug withdrawal headache; headache; migraine; migraine with aura; migraine without aura; ophthalmoplegic migraine; post-traumatic headache; postictal headache; retinal migraine; sUnCT syndrome; sinus headache; status migrainosus; temporomandibular joint syndrome; tension headache; typical aura without headache hyperglycemia/newonset diabetes mellitus (sMQ hyperglycemia/ new-onset diabetes mellitus) (narrow) Blood 1,5-anhydroglucitol decreased; blood glucose increased; diabetes complicating pregnancy; diabetes mellitus; diabetes mellitus inadequate control; diabetes with hyperosmolarity; diabetic coma; diabetic hyperglycemic coma; diabetic hyperosmolar coma; diabetic ketoacidosis; diabetic ketoacidotic hyperglycemic coma; fructosamine increased; gestational diabetes; glucose tolerance impaired; glucose tolerance impaired in pregnancy; glucose urine present; glycosuria; glycosuria during pregnancy; glycosylated hemoglobin increased; hyperglycemia; hyperglycemic hyperosmolar nonketotic syndrome; impaired fasting glucose; insulin resistance; insulin resistance syndrome; insulin-resistant diabetes; insulin-requiring Type 2 diabetes mellitus; ketoacidosis; ketonuria; ketosis; latent autoimmune diabetes in adults; metabolic syndrome; neonatal diabetes mellitus; pancreatogenous diabetes; Type 1 diabetes mellitus; Type 2 diabetes mellitus; urine ketone body present hypertension accelerated hypertension; blood pressure ambulatory increased; blood pressure diastolic increased; blood pressure inadequately controlled; blood pressure increased; blood pressure orthostatic increased; blood pressure systolic increased; diastolic hypertension; endocrine hypertension; essential hypertension; hypertension; hypertensive angiopathy; hypertensive cardiomegaly; hypertensive cardiomyopathy; hypertensive crisis; hypertensive emergency; hypertensive encephalopathy; hypertensive heart disease; hypertensive nephropathy; labile hypertension; liddle's syndrome; malignant hypertension; malignant hypertensive heart disease; malignant renal hypertension; mean arterial pressure increased; neurogenic hypertension; orthostatic hypertension; paradoxical pressor response; procedural hypertension; renal hypertension; renovascular hypertension; secondary hypertension; systolic hypertension Insomnia Initial insomnia; insomnia; middle insomnia; poor quality sleep; sleep disorder; sleep phase rhythm disturbance; somnambulism Ischemic heart disease (sMQ ischemic heart disease sub-sMQ other ischemic heart disease) (broad) angina pectoris; angina unstable; arteriogram coronary abnormal; arteriosclerosis coronary artery; arteriospasm coronary; cardiac stress test abnormal; computerized tomogram; coronary artery abnormal; coronary angioplasty; coronary arterial stent insertion; coronary artery bypass; coronary artery disease; coronary artery dissection; coronary artery insufficiency; coronary artery restenosis; coronary artery stenosis; coronary endarterectomy; coronary no-reflow phenomenon; coronary ostial stenosis; coronary revascularization; dissecting coronary artery aneurysm; electrocardiogram signs of myocardial; electrocardiogram sT segment depression; electrocardiogram sT-T segment abnormal; electrocardiogram sT-T segment depression; electrocardiogram T-wave abnormal; electrocardiogram T-wave inversion; exercise electrocardiogram abnormal; exercise test abnormal; external counterpulsation; hemorrhage coronary artery; in-stent coronary artery restenosis; ischemic cardiomyopathy; microvascular angina; myocardial ischemia; other ischemic heart disease (broad) ischemia; percutaneous coronary intervention; prinzmetal angina; stress cardiomyopathy; stress echocardiogram abnormal; subclavian coronary steal; syndrome; subendocardial ischemia aphthous stomatitis; mouth ulceration; oral mucosal eruption; oropharyngeal blistering; stomatitis; stomatitis hemorrhagic; stomatitis necrotizing stroke amaurosis fugax; basal ganglia hemorrhage; basilar artery occlusion; basilar artery thrombosis; brachiocephalic artery occlusion; brain stem hemorrhage; brain stem infarction; brain stem ischemia; brain stem stroke; brain stem thrombosis; carotid aneurysm rupture; carotid arterial embolus; carotid artery occlusion; carotid artery thrombosis; central nervous system hemorrhage; cerebellar artery occlusion; cerebellar artery thrombosis; cerebellar embolism; cerebellar hematoma; cerebellar hemorrhage; cerebellar infarction; cerebellar ischemia; cerebral arteriovenous malformation hemorrhagic; cerebral artery embolism; cerebral artery occlusion; cerebral artery thrombosis; cerebral hematoma; cerebral hemorrhage; cerebral hemorrhage fetal; cerebral hemorrhage neonatal; cerebral infarction; cerebral infarction fetal; cerebral ischemia; cerebral thrombosis; cerebrovascular accident; embolic cerebral infarction; embolic stroke; hemorrhage intracranial; hemorrhagic cerebral infarction; hemorrhagic stroke; hemorrhagic transformation stroke; intracranial hematoma; intracranial tumor hemorrhage; intraoperative cerebral artery occlusion; intraventricular hemorrhage; intraventricular hemorrhage neonatal; ischemic cerebral infarction; ischemic stroke; lacunar infarction; lateral medullary syndrome; pituitary hemorrhage; pituitary infarction; postprocedural stroke; precerebral artery occlusion; putamen hemorrhage; reversible ischemic neurological deficit; ruptured cerebral aneurysm; stroke in evolution; subarachnoid hemorrhage; subarachnoid hemorrhage neonatal; subdural hemorrhage neonatal; thalamic infarction; thalamus hemorrhage; thrombotic cerebral infarction; thrombotic stroke; transient ischemic attack; vertebral artery dissection; vertebral artery occlusion; vertebral artery thrombosis supraventricular tachycardia atrial tachycardia; postural orthostatic tachycardia syndrome; sinus tachycardia; supraventricular tachycardia; tachycardia paroxysmal syncope loss of consciousness; presyncope; syncope Tachycardia heart rate increased; sinus tachycardia; tachycardia Urinary retention Bladder neck obstruction; residual urine volume increased; urinary hesitation; urinary retention; urinary retention postoperative; urinary tract obstruction; urine flow decreased (Continued)
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